Lung Cancer
Read Time: 2 mins

Role of 4D Stereotactic Radiotherapy with the CyberKnife® System in the Treatment of Lung Cancer

Copy Link
Published Online: May 15th 2012 European Oncology & Haematology, 2012;8(3):189-191 DOI:
Authors: Joost J Nuyttens, Pierre-Yves Bondiau
Quick Links:
Article Information

Lung cancer remains in 2012 the leading cause of cancer-related deaths within the European Union. Although surgery still constitutes the standard treatment for lung cancer, it is not feasible for a large number of patients. Treatment of lung tumours thus requires an innovative treatment solution. The ability of the CyberKnife® stereotactic radiotherapy system to track and automatically correct for respiratory motion allows an increase of the radiation dose, and thus gives the opportunity to improve the efficacy of the treatment. In this article, an overview of this technology and its clinical benefits is provided and shows that it can offer an effective and safe option in the treatment of lung tumours, whether they are primary and early-stage, recurrent or secondary, as well as peripheral or central.


Lung cancer, stereotactic body radiation therapy (SBRT), CyberKnife® system, mobile targets, Synchrony® tracking system, early-stage lung cancer, peripheral lung tumour, central lung tumour, re-irradiation


Lung cancer has been the world’s most frequent cancer, as well as the world’s leading cause of cancer-related deaths, for several decades.1 It remains today the leading cancer in males2 and, even if incidence rates are generally lower, it represents among females the fourth most frequent cancer and the second most common cause of death from cancer.1 Furthermore, the distribution of histological subtypes has considerably changed over the recent decades, with an increasing frequency of adenocarcinoma compared with squamous cell carcinoma.3 In the European Union, in 2008, lung cancer represented an incidence of 391,000, making it the third most frequent cancer after colorectal and breast cancer.4 However, with an estimated 342,000 related deaths in 2008, it is the number one killer cancer.4 Although the mortality rate in men has been decreasing for more than 20 years, the mortality rate in women has been increasing in many European countries2 and rose from 12.6/100,000 in 2007 to 13.1/100,000 in 2011.5 As a consequence, it tends to approach and sometimes exceed the mortality rate of breast cancer, as was the case in the UK and Poland, where lung cancer was the leading cause of cancer-related deaths in women from 2007 to 2008. The lung cancer epidemic in women is still expanding.6 Predictions for the year 2012 show a 7 % increase of lung cancer in European females.5

Treatments for Patients with Lung Cancer and Their Side Effects
Clinical management and prognosis of lung cancer depend on the histological type of cancer, its stage and the general state of health of the patient. Non-small-cell lung cancer (NSCLC, 75–80 % of lung cancers) is primarily treated with surgery, while limited small-cell lung cancer (SCLC, 20–25 % of lung cancers) is usually treated with chemotherapy and radiotherapy.

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:

The authors have no conflicts of interest to declare.


Joost J Nuyttens, Erasmus MC-Daniel den Hoed Cancer Center, Department of Radiation Oncology, Postbus 2040–3000 CA, Rotterdam, The Netherlands. E:


The publication of this article was funded by Accuray®. The views and opinions expressed are those of the authors and not necessarily those of Accuray®.




  1. Ferlay J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 2010;127:2893–917.
  2. Jemal A, Bray F, Center MM, et al., Global cancer statistics, CA Cancer J Clin, 2011;61:69–90.
  3. Quoix E, Lemarié E, Epidemiological novelties in lung cancer, Rev Mal Respir, 2011;28:1048–58.
  4. Ferlay J, Parkin DM, Steliarova-Foucher E., Estimates of cancer incidence and mortality in Europe in 2008, Eur J Cancer, 2010;46:765–81.
  5. Malvezzi M, Bertuccio P, Levi F, et al., European cancer mortality predictions for the year 2012, Ann Oncol, 2012;23:1044–52.
  6. Malvezzi M, Arfe A, Bertuccio P, et al., European cancer mortality predictions for the year 2011, Ann Oncol, 2011;22:947–56.
  7. Strand T-E, Rostad H, Damhuis RAM, et al., Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude, Thorax, 2007;62:991–7.
  8. Mountain CF, Revisions in the international system for staging lung cancer, Chest, 1997;111:1710–7.
  9. Munden RF, Swisher SS, Stevens CW, et al., Imaging of the patient with non-small cell lung cancer, Radiology, 2005;237:805–18.
  10. Handy JR Jr, Asaph JW, Skokan L, et al., What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery, Chest, 2002;122:21–30.
  11. Schulte T, Schniewind B, Dohrmann P, et al., The extent of lung parenchyma resection significantly impacts long-term quality of life in patients with non-small cell lung cancer, Chest, 2009;135:322–9.
  12. Prevost JB, Voet P, Hoogeman M, et al. Four-dimensional stereotactic radiotherapy for early stage non-small cell lung cancer: a comparative planning study, Technol Cancer Res Treat, 2008;7:27–33.
  13. Martin A, Gaya A., Stereotactic body radiotherapy: a review, Clin Oncol, 2010;22:157–72.
  14. Lartigau E, Mirabel X, Prevost B, et al., Extracranial stereotactic radiotherapy: preliminary results with the CyberKnife, Onkologie, 2009;32:209–15.
  15. Seppenwoolde Y, Berbeco RI, Nishioka S, et al., Accuracy of tumor motion compensation algorithm from a robotic respiratory tracking system: a simulation study, Med Phys, 2007;34:2774–84.
  16. Thariat J, Li G, Angellier G, et al., Current indications and ongoing clinical trials with CyberKnife stereotactic radiotherapy in France in 2009, Bull Cancer, 2009;96:853–64.
  17. Hoogeman M, Prévost JB, Nuyttens J, et al., Clinical accuracy of the respiratory tumor tracking system of the cyberknife: assessment by analysis of log files, Int J Radiat Oncol Biol Phys, 2009;74:297–303.
  18. Kilby W, Dooley JR, Kuduvalli G, et al., The CyberKnife Robotic Radiosurgery System in 2010, Technol Cancer Res Treat, 2010;9:433–52.
  19. Nuyttens JJ, Prévost J-B, Praag J, et al., Lung tumor tracking during stereotactic radiotherapy treatment with the CyberKnife: marker placement and early results, Acta Oncol, 2006;45:961–5.
  20. Brown WT, Wu X, Fayad F, et al., CyberKnife radiosurgery for stage I lung cancer: results at 36 months, Clin Lung Cancer, 2007;8:488–92.
  21. Brown WT, Wu X, Fayad F, et al., Application of robotic stereotactic radiotherapy to peripheral stage I non-small cell lung cancer with curative intent, Clin Oncol, 2009;21:623–31.
  22. Bibault JE, Prevost B, Dansin E, et al., Stereotactic radiotherapy for lung cancer: non-invasive real-time tumor tracking, Cancer Radiother, 2010;14:690–7.
  23. Taste H, Beckendorf V, Bernier V, et al., Extracranial stereotactic radiotherapy avancer by robotic radiosurgery: preliminary experience of the center Alexis-Vautrin, Bull Cancer, 2009;96:865–74.
  24. Vahdat S, Oermann EK, Collins SP, et al., CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment, J Hematol Oncol, 2010;3:6.
  25. Collins BT, Vahdat S, Erickson K, et al., Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer, J Hematol Oncol, 2009;2:1.
  26. Coon D, Gokhale AS, Burton SA, et al., Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning, Clin Lung Cancer, 2008;9:217–21.
  27. Van der Voort van Zyp NC, Prévost JB, Hoogeman MS, et al., Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome, Radiother Oncol, 2009;91:296–300.
  28. Van der Voort van Zyp NC, van der Holt B, van Klaveren RJ, et al., Stereotactic body radiotherapy using real-time tumor tracking in octogenarians with non-small cell lung cancer, Lung Cancer, 2010;69:296–301.
  29. Van der Voort van Zyp NC, Prévost JB, van der Holt B, et al., Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer, Int J Radiat Oncol Biol Phys, 2010;77:31–7.
  30. Nuyttens JJ, van der Voort van Zyp NC, Praag J, et al., Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors, Radiother Oncol, 2012;102:383–7.
  31. Bondiau PY, Doyen J, Mammar H, et al., [Reirradiation of spine and lung tumor with CyberKnife], Cancer Radiother, 2010;14:438–41.

Further Resources

Share this Article
Related Content In Lung Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72